22 May 2013
Keywords: sankyo, develop, searle, xemilofiban, japan, negotiated, rights
Article | 07 August 1995
Sankyo has negotiated rights to codevelop and comarket Searle's novel
antiplatelet agent xemilofiban in Japan. The drug is an orally-active
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 August 1995
31 July 1995
14 August 1995
© 2013 thepharmaletter.com